The Role of 750 mg Once-Daily Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Diseases
References
| 1. | Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-52. |
| 2. | Murray CJL, Lopez AD. Alternative visions of the future: projecting mortality and disability, 1990-?2020. In: Murray CJL, Lopez AD, editors. The global burden of disease. Cambridge (Massachusetts): Harvard University Press; +1996. pp. 325-97. |
| 3. | Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117: 380-5. |
| 4. | Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-71. |
| 5. | Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, MD, Sagnier PP; the MOSAIC Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-64. |
| 6. | Fish DN. Levofloxacin: update and ?perspectives on one of the original ‘respiratory quinolones’. Expert Rev ?Anti-infect Ther 2003; 1: 371-87. |
| 7. | Martinez FJ, Grossman RF, Zadeikis N, Fisher AC, Walker K, Ambruzs ME, Tennenberg AM. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005; 25: 1001-10. |
| 8. | Balter MS, La Forge J, Low DE, Mandell L, Grossman RF; Canadian Thoracic Society; Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003;10 (Suppl B): 3B-32B. |
| 9. | Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004; 48: 56-65. |
| 10. | Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens – a global perspective. Semin Respir Infect 2000; 15: 195-207. |
| 11. | Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43: 1310-3. |
| 12. | Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-9. |
| 13. | Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin.Clin Infect Dis 2000; 31: 613-5. |
| 14. | Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31:1008-11. |
| 15. | Musher DM, Dowell ME, Shortridge VD, Flamm RK, Jorgensen JH, Le Magueres P, Krause KL. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 630-1. |
| 16. | Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118: 1839-40. |
| 17. | Grossman RF, Ambrusz ME, Fisher AC, Khashab MM, Kahn JB. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. Clin Ther 2006: 28: 1175-80. |
| 18. | Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752-60. |
| 19. | Poole M, Anon J, Paglia M, Xiang J, Khashab M, Kahn J. A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg 2006; 134: 10-7. |
| 20. | Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112: 310-3. |
| 21. | Khashab MM, Xiang J, Kahn JB. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin 2006; 22: 1997-2006. |
| 22. | Global Initiative for Chronic Obstrctive Lung Disease (GOLD). Global strategy for diagnosis, namagement, and prevention of COPD. www/goldcopd.com. |
| 23. | American Thoracic Society / European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. Internet Version 1.2. New York: American Thoracic Society; 2004 [updated 2005 September 8]. Available from: http://www.thoracic.org/go/copd. |
 |
 |
LATEST TOPICS
RELATED ARTICLES
